GlassScriptPhysician profile
Kyanne Lamay Wright
NPI 1649991316
$2,418.12
in general payments reported to CMS, 2019-2025
20 companies · $496 in 2025
The $496 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $131 · 2023: $1,268 · 2024: $523 · 2025: $496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,286.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $541.98 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $323.98 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Corium, LLC | $259.56 | 2022-2025 | Azstarys |
| Tris Pharma INC | $206.75 | 2023-2025 | Dyanavel Xr |
| Alkermes, INC. | $140.84 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Ironshore Pharmaceuticals INC. | $130.60 | 2022-2024 | Jornay Pm |
| Lundbeck LLC | $128.75 | 2022-2023 | Rexulti |
| Abbvie INC. | $115.77 | 2023-2025 | |
| Axsome Therapeutics, INC. | $112.94 | 2022-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $98.25 | 2022-2025 | Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $69.32 | 2023-2025 | Austedo Xr, Uzedy |
| Vanda Pharmaceuticals INC. | $56.03 | 2024-2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $52.67 | 2024-2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $51.97 | 2023-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $27.97 | 2025 | Cobenfy |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $24.31 | 2023 | Ingrezza |
| Braeburn INC. | $20.98 | 2023 | Brixadi |
| Idorsia Pharmaceuticals US INC | $20.88 | 2024 | Quviviq |
| Indivior INC. | $17.72 | 2024 | Perseris |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.85 | 2025 | Rejoyn |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyanne Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.